Transient neonatal diabetes mellitus (TNDM) is a genetically heterogeneous form of neonatal diabetes characterized by hyperglycemia that remits during infancy with a tendency to recur in later life. This case report presents the history of a male infant with transient neonatal diabetes mellitus. The patient was treated with a continuous subcutaneous insulin infusion (CSII) and a continuous glucose monitoring (CGM) system until the age of 2 months, when the normoglycemia connected with a withdrawal of treatment was noted. The genetic test results excluded the majority of known mutations related to TNDM. This case report focuses on various genetic mutations and the clinical features connected with them that cause TNDM and highlights the difficulties in the diagnostic and therapeutic processes of this disease. CSII and CGM systems seem to be a safe and effective treatment option in TNDM and may be used in the therapy.

Background: The MiniMed 780G was the first commercially available automated insulin delivery (AID) system in Poland. The aim of this study was to analyze glycemic management in children with type 1 diabetes (T1D) after three years of using the system. Materials and methods: The data included anthropometric measurements, information from insulin pumps, and continuous glucose monitoring (CGM) from fifty children with T1D (mean age: 9.9 ± 2.4 years; T1D duration at baseline: 3.9 ± 2.56 years) using the MiniMed 780G. The data were collected at AID initiation, 12 and 36 months after starting its use. Results: Coefficient of variation (CV) and body mass index (BMI) z-scores at baseline and after 3 years were comparable (p > 0.05). TITR firstly increased after the AID system implementation with the peak value after 6 months (60.82% ± 9.34), then the values decreased to 56.50%± 10.78% after 3 years (p<0.001). Time in range (70–180 mg/dL) decreased after 3 years of observation compared to peak values at 6 and 12 months (77.74% ± 7.65% versus 81.16% ± 7.83% and 80.40% ± 8.25%, respectively, p<0.005. The percentage of auto-correction in total daily insulin dose increased significantly (11.24% ± 6.08% 2 weeks of AID system usage vs. 16.34% ± 6.69% after 3 years; p < 0.001). Conclusions: Despite a slight deterioration after 3 years, optimal glycemic management was maintained throughout the observation period. GCM metrics remained within recommended values in early adolescence, most likely due to auto-correction boluses.

Background: Cystic fibrosis-related diabetes (CFRD) is a common comorbidity in cystic fibrosis (CF), particularly in the pediatric population. As cystic fibrosis transmembrane conductance regulator modulators (CFTRm) become widely used, there is growing interest in their potential metabolic benefits. This systematic review evaluates the effects of CFTR modulators on glucose metabolism and glycemic control in children and adolescents with CFRD. Materials and methods: Following PRISMA guidelines, we conducted a literature search in PubMed, Scopus, and Medline for all papers until 2025. Eligible studies included clinical trials, observational studies, chart reviews, and case reports focusing on pediatric patients receiving CFTRm. Results: From almost 653 initially identified records 5 studies met inclusion criteria - 1 clinical trial, 2 observational studies and 2 case reports. Evidence suggests CFTRm may improve glucose tolerance and insulin secretion in some pediatric patients, particularly in those with preserved β-cell function or early-stage CFRD. However, results varied across studies with some showing no significant improvements in glycemic control. Conclusions: While early findings suggest CFTR modulators may offer metabolic benefits and potentially delay or reduce the need for insulin therapy in children CFRD, current evidence is limited. Larger, pediatric-focused clinical trials with standardized glycemic outcomes are essential to determine the long-term efficacy and safety of CFTRm in managing or preventing CFRD.

Introduction: MiniMed 780G was the first automated insulin delivery (AID) system approved in Poland. Although it has been studied extensively, there are relatively less data regarding its use in children with type 1 diabetes from the onset of the disease. We aimed to evaluate and compare glycemic parameters in children treated from type 1 diabetes onset with either an AID system or a pump with predictive‐low glucose suspend (SAP‐PLGS). Material and Methods: We retrospectively gathered anthropometric data and systems records of 50 children with a newly diagnosed type 1 diabetes, 22 using an AID system (aged 9.66 ± 3.76 years), and 28 using a SAP‐PLGS device (aged 8.13 ± 4.2 years). Glycemic parameters and other collected data were compared at four different time points: the first 2 weeks using the insulin pump and 2 weeks after 3, 6, and 12 months of insulin therapy. Results: After the first year of treatment, we found in the AID group higher time in range (TIR) 70–180 mg/dL ( P = 0.001) as well as time in tight range (TITR) 70–140 mg/dL ( P = 0.0003). There were no significant differences in the C‐peptide level after 1 year of treatment between the two studied groups ( P = 0.41). Conclusions: Using the AID system from the onset of type 1 diabetes resulted in improved glycemic control parameters in the studied children compared with using SAP‐PLGS. The C‐peptide preservation was comparable in both analyzed groups.